| 000 | 01801 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515012623.0 | ||
| 264 | 0 | _c20060927 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1093/annonc/mdj121 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRyan, B M | |
| 245 | 0 | 0 |
_aSurvivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2006 |
||
| 300 |
_a597-604 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 |
_aBreast Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitor of Apoptosis Proteins |
| 650 | 0 | 4 |
_aMicrotubule-Associated Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xmetabolism |
| 650 | 0 | 4 |
_aPlasminogen Activator Inhibitor 1 _xmetabolism |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 | _aSurvivin |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrokinase-Type Plasminogen Activator _xmetabolism |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xmetabolism |
| 700 | 1 | _aKonecny, G E | |
| 700 | 1 | _aKahlert, S | |
| 700 | 1 | _aWang, H-J | |
| 700 | 1 | _aUntch, M | |
| 700 | 1 | _aMeng, G | |
| 700 | 1 | _aPegram, M D | |
| 700 | 1 | _aPodratz, K C | |
| 700 | 1 | _aCrown, J | |
| 700 | 1 | _aSlamon, D J | |
| 700 | 1 | _aDuffy, M J | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 17 _gno. 4 _gp. 597-604 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdj121 _zAvailable from publisher's website |
| 999 |
_c16020881 _d16020881 |
||